Garbuzenko O

ORCID: 0009-0007-0153-4150 · 1 paper in corpus

2024

Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells.

Cancer cell international ·doi:10.1186/s12935-024-03469-0

BackgroundOlaparib is a PARP inhibitor inducing synthetic lethality in tumors with deficient homologous recombination (HRD) caused by BRCA1/2 mutations. The FDA has approved monotherapy for first-line platinum-sensitive, recurrent high-grad…